BFRIBiofrontera Inc.
Is Biofrontera struggling financially?
Yes, by its own account. Biofrontera told the SEC on 14 May 2026, in Form 10-Q, that there is substantial doubt about its ability to continue as a going concern.
Going concern disclosed May 2026
15/100
Critical
- Sector
- Biotech/Pharma
- Market cap
- $22.0M
- Source filing
- 10-Q 14 May 2026
- Balance sheet
- 30 Jun 2026
Cash runway
-
3months
If the burn speeds up
Empty by Sep 2026
-
5months
If it eases off
Empty by Nov 2026
Both rows are the same reported burn flexed 15% either way, and neither assumes the company raises a cent.
Out of cashTwo years or more
The runway math
Cash and short-term investments
$4.7M
÷
Cash burned over the last 12 months
$15.2M
What Biofrontera told the SEC
…and maintaining the business strategy for a period of twelve months from the issuance date of this report. Management believes that these conditions raise substantial doubt about the Company’s ability to continue as a going concern for at least twelve months from the issuance date of this Quarterly Report on Form 10-Q. The Company plans to address the conditions that raise substantial doubt regarding its ability…
Biofrontera Inc., Form 10-Q, filed 14 May 2026.
Read the filing on SEC.govWhat this means
- Not a bankruptcy filing, and not a prediction.
- It is the company’s own statement, agreed with its auditor, that the doubt is material enough to disclose.
- The runway is arithmetic on two reported numbers, not a forecast. Companies carry this language for years, raise money and keep going.
What else the numbers show
- 35.1% share-count increase The company issued stock. Each share now owns 26.0% less of the business than a year ago, before any change in the price.
- Cash burn is narrowing It is spending 30% less cash per year than it was, so the runway above is lengthening rather than shortening.
Other Biotech/Pharma companies that filed the doubt
- LGVN Longeveron $26.9M
- BIVI BioVie $16.5M
- CELU Celularity $23.2M
- LEXX Lexaria Bioscience $18.0M
- DRIO DarioHealth $73.4M
- NDRA Endra Life Sciences $6.7M